Skip to main content
logo
Sangamo Therapeutics, Inc. (SGMOQ)
OTCMKTS · Delayed Price · Currency is USD
0.1160
-0.0039 (-3.25%)
At close: Oct 30, 2026

Sangamo Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
34.5639.5557.8176.23111.3110.7
Revenue Growth
-45.80%-31.57%-67.20%58.34%0.54%-6.34%
Gross Profit
-78.68-73.12-53.52-54.23-138.6-120.12
Operating Income
-110.32-108-98.25-114.29-201.28-183.34
Net Income
-123.33-122.93-97.94-257.83-192.28-178.29
Earnings Per Share
-0.38-0.44-0.49-1.48-1.25-1.23
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
27.5920.9541.9281307.48464.72
Total Debt
19.3326.830.5738.143.1148.08
Net Cash (Debt)
8.25-5.8511.3542.9264.37416.64
Net Cash Growth
2615.13%--73.54%-83.77%-36.55%-35.89%
Net Cash Per Share
0.03-0.020.060.251.712.88

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-90.34-97.21-67.14-224.84-223.63-233.25
Capital Expenditures
-0.12-0.1-0.27-21.16-20.17-23.28
Free Cash Flow
-90.46-97.31-67.41-246-243.8-256.53
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-227.67%-184.86%-92.60%-30.77%-124.53%-108.51%
Operating Margin
-319.25%-273.07%-169.98%-64.85%-180.85%-165.62%
Pretax Margin
-358.88%-312.25%-169.74%-149.18%-172.37%-160.79%
Profit Margin
-356.89%-310.81%-169.45%-146.30%-172.76%-161.05%
FCF Margin
-261.76%-246.03%-116.62%-139.59%-219.05%-231.73%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-205.04205.04---
PS Ratio
1.393.573.680.554.629.87